文献速递产科母胎医学

蛋白酶激活受体1的妊娠特异性表达:预防和治疗子痫前期的一个治疗靶点?

Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?
PubMed 文献 · Am J Obstet Gynecol · 2022-01-01

本文综述中性粒细胞在子痫前期中浸润母体血管的机制,提出妊娠特异性表达的蛋白酶激活受体1(PAR1)可能是子痫前期的治疗靶点。子痫前期女性血管PAR1表达增加8倍,PAR1激活通过RhoA激酶和核因子-κB通路介导炎症反应,阿司匹林可阻断该下游通路。FDA近期批准一种PAR1抑制剂,为测试其预防和/或治疗子痫前期提供了机会。

要点

  • 中性粒细胞仅在妊娠期表达PAR1,子痫前期时血管PAR1表达增加8倍。
  • PAR1激活通过RhoA激酶使核因子-κB入核,促进炎症基因表达。
  • 低剂量阿司匹林是高风险女性预防子痫前期的标准治疗,可能通过抑制环氧合酶-2阻断下游通路。

核心结论

  • 妊娠特异性PAR1表达可能是子痫前期病理生理的关键,应考虑将PAR1抑制作为治疗手段。
  • FDA近期批准一种PAR1抑制剂,为测试其能否预防和/或治疗子痫前期提供了机会,但标准剂量阿司匹林可能通过阻断其下游作用同样有效。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 子痫前期女性血管PAR1表达增加8倍,PAR1也表达于胎盘这一妊娠特异性组织。
  • 正常妊娠女性中性粒细胞中PAR1的蛋白酶激活引起RhoA激酶活化,使核因子-κB从胞质转位至胞核,增加炎症基因表达。
  • 子痫前期女性的中性粒细胞已处于活化状态,核因子-κB定位于细胞核;抑制PAR1或RhoA激酶可导致核因子-κB从细胞核外流回细胞质。
  • 环氧合酶-2似乎是PAR1与RhoA激酶之间的下游介质,因为阿司匹林抑制核因子-κB的核转位并抑制中性粒细胞产生超氧化物、血栓素和肿瘤坏死因子α。
  • 近期研究显示阿司匹林的有益效应延伸至胎盘,纠正了血栓素增加与前列环素减少的失衡及氧化应激。

关键数值与推荐

  • 子痫前期女性血管PAR1表达增加8倍。
  • 子痫前期中升高并激活PAR1的两种蛋白酶为基质金属蛋白酶-1和中性粒细胞弹性蛋白酶。

临床怎么用

  • 目前低剂量阿司匹林是高风险女性预防子痫前期的标准治疗。
  • 作者认为应考虑将PAR1抑制作为子痫前期的治疗手段。
  • FDA近期批准一种PAR1抑制剂,为测试其能否预防和/或治疗子痫前期提供了机会。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neutrophils extensively infiltrate maternal blood vessels in preeclampsia. This could explain why multiple organs are affected in this enigmatic disorder. Lipid peroxides produced by the placenta are probably the first factors that activate neutrophils as they circulate through the intervillous space, but then a second factor specific to pregnancy comes into play, protease-activated receptor 1. The only time neutrophils express protease-activated receptor 1 is during pregnancy. This means that neutrophils can be activated by a mechanism specific to pregnancy, that is, by proteases. Two proteases that are elevated in preeclampsia and activate protease-activated receptor 1 are matrix metalloproteinase-1 and neutrophil elastase. There is an 8-fold increase in vascular protease-activated receptor 1 expression in women with preeclampsia, and protease-activated receptor 1 is also expressed on the placenta, a pregnancy-specific tissue. The question arises if the pregnancy-specific expression of protease-activated receptor 1 is essential to the pathophysiology of preeclampsia. Protease activation of protease-activated receptor 1 in neutrophils of women with normal pregnancies causes activation of RhoA kinase. RhoA kinase phosphorylates nuclear factor-kappa B causing its translocation from the cytosol into the nucleus, increasing the expression of inflammatory genes. This signaling pathway is blocked by inhibition of either protease-activated receptor 1 or RhoA kinase activity. In contrast, neutrophils obtained from preeclamptic women are already activated, with nuclear factor-kappa B localized in the nucleus. Surprisingly, inhibition of either protease-activated receptor 1 or RhoA kinase results in an efflux of nuclear factor-kappa B from the nucleus back into the cytoplasm. Cyclooxygenase-2 seems to be a downstream mediator between protease-activated receptor 1 and RhoA kinase because aspirin inhibits the nuclear translocation of nuclear factor-kappa B and inhibits neutrophil production of superoxide, thromboxane, and tumor necrosis factor alpha. Currently, low-dose aspirin is the standard of care to prevent preeclampsia in high-risk women. Generally, the actions of low-dose aspirin are attributed to selective inhibition of maternal platelet thromboxane production. However, a recent study showed that beneficial effects extend to the placenta, where aspirin corrected the imbalance of increased thromboxane and reduced prostacyclin and oxidative stress. Selective inhibition of placental thromboxane is possible because thromboxane and prostacyclin are compartmentalized. Thromboxane is produced by trophoblast cells and prostacyclin by endothelial cells, so as aspirin crosses the placenta, its levels decline, sparing prostacyclin. Placental oxidative stress is attenuated because cyclooxygenase-2 inhibition decreases the generation of reactive oxygen species to decrease the formation of isoprostanes. The clinical manifestations of preeclampsia can be explained by protease activation of protease-activated receptor 1 in different tissues. In neutrophils, it can account for their activation and inflammatory response. In vascular tissue, protease-activated receptor 1 activation leads to enhanced vascular reactivity to angiotensin II to cause hypertension. In the placenta, it leads to oxidative stress, increased soluble fms-like tyrosine kinase, and thromboxane production. Activation of protease-activated receptor 1 on endothelial cells causes contraction, leading to edema and proteinuria, and activation on platelets leads to coagulation abnormalities. As proteases that activate protease-activated receptor 1 are elevated in the circulation of women with preeclampsia, consideration should be given to the inhibition of protease-activated receptor 1 as a treatment. Recently, The Food and Drug Administration (FDA) approved a protease-activated receptor 1 inhibitor, creating an opportunity to test whether protease-activated receptor 1 inhibition can prevent and/or treat preeclampsia, but a standard dose of aspirin might be just as effective by blocking its downstream actions.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Walsh SW, Strauss JF. Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia? Am J Obstet Gynecol. 2022. PMID: 35177224. doi:10.1016/j.ajog.2021.11.1367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。